MD Anderson Cancer Center and AbbVie have entered a three-year immunotherapy collaboration to efficiently select and conduct preclinical and clinical studies evaluating new ideas in the area of immuno-oncology. AbbVie’s research efforts in immunotherapy leverage the company’s strengths in biology, protein engineering and chemistry. MD Anderson’s immunotherapy platform includes technology for preclinical modeling, clinical trials and immune monitoring before, during and after...